ALS is a rare but fatal progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord (Doi et al., 2014). ALS is often referred to as “Lou Gehrig’s Disease” after the famous baseball player. ALS severely impacts physical functioning, and initially presents with muscle twitching, weakness in an arm or leg, or sometimes with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death.
GlobalData epidemiologists used age- and sex-specific diagnosed prevalence rates to forecast the diagnosed prevalent cases, and used the diagnosis rate and diagnosed prevalence to calculate total prevalent cases taking into account the significant relationship between age and ALS prevalence. GlobalData epidemiologists applied country-specific prevalence rates of ALS, wherever available, to each country’s population to obtain the number of estimated diagnosed prevalent cases.
The following data describes epidemiology of ALS cases. In 2017, the 7MM had 46,240 diagnosed prevalent cases of ALS. This is expected to increase to 52,712 diagnosed prevalent cases by 2027, at an Annual Growth Rate (AGR) of 1.40%. The increase is driven by the aging population in the 7MM. In 2017, the 7MM had 53,024 total prevalent cases of ALS. This is expected to increase to 60,304 total prevalent cases by 2027, at an AGR of 1.37%. The US had the highest number of diagnosed prevalent and total prevalent cases of ALS. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.
The Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast Report and Epidemiology Forecast Model provide an overview of the risk factors and global trends of ALS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
This report also includes a 10-year epidemiological forecast for the following segmentations in ages 40 years and older across the 7MM: 10-year epidemiological forecast for the total (medically diagnosed and undiagnosed) and diagnosed prevalent cases of ALS. The diagnosed prevalent cases are further segmented by age (40 years and older), sex, and type of ALS based on sporadic and familial component.
The ALS epidemiology forecast report and model were written and developed by Masters- and PhD-level epidemiologists.
The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.
The Epidemiology Forecast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to buy
The ALS Epidemiology Forecast series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global ALS market.
Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ALS therapeutics in each of the markets covered.
Understand proportion of ALS population based on sporadic and familial component.